AAV vectors are the holy grail of gene therapy. These viral tools introduce "payload genes" into different tissues often with great precision. They do not cause disease and have a proven safety record in clinical trials. Thus, their use has the potential to provide safe and long-term relief for genetic and/or chronic diseases.
AAVogen is developing a gene therapy for muscle wasting diseases, especially inclusion body myositis, Duchenne muscular dystrophy and cancer cachexia. In pre-clinical studies, AVGN7 stabilizes muscle structure and increases muscle mass, strength and exercise capacity. It also prevents muscle wasting.
Cardiac and skeletal muscle wasting go hand-in-hand. Indeed, addressing cardiac and respiratory failure is key to preventing mortality in many muscle wasting diseases. In pre-clinical studies, AVGN7 corrects deficits in cardiac muscle structure and in addition, improves cardiac output during strenuous exercise.
At AAVogen, it's personal
Our mission is to make you stronger. The company was founded by a family directly impacted by two muscle wasting diseases: Duchenne muscular dystrophy and cancer cachexia. Our fight is personal and is shared by affected families across the globe and our commitment to developing better and more effective therapies is undaunted.
AVGN7 prevents muscle wasting in animals with cancer and can restore muscle mass and strength even after wasting has already occurred. It works when injected directly into muscle or when administered systemically to all muscles. It was also designed to avoid the potentially serious side-effects of other "myostatin attenuating" therapies.
AVGN7 for the durable maintenance of muscle mass and function.
We understand the challenges of fighting a muscle wasting disease. We also understand the role education plays in empowering patients.
If you have questions about AAVogen or AVGN7, about gene therapy in general or even different muscle wasting diseases, please contact us. You can also learn more about investing and collaborating with AAVogen by visiting the link to the right.
Whether you're curious, scared or intrigued, we want to hear from you.